CRENESSITY Delivers 2-Year Data in CAH: Less Steroids, Same Control?

For decades, treating congenital adrenal hyperplasia meant a trade-off: control hormones, but accept long-term steroid damage. Now, new two-year data suggest that trade-off may finally be shifting. Neurocrine Biosciences has reported durable Phase III results for CRENESSITY, showing sustained reductions in glucocorticoid (GC) exposure—without losing disease control.

The Headline: Lower Steroids, Sustained Outcomes

From the Phase III CAHtalyst Adult study:

• ~70% of patients reached physiologic GC dosing at 2 years
• 38% average reduction in daily glucocorticoid dose
• No loss of androgen control (key risk avoided)

Even more telling:

• 75% of patients on dexamethasone transitioned off it
• Many reduced dosing frequency or eliminated extra doses entirely

This isn’t incremental. It directly addresses one of the biggest problems in CAH treatment.

Why This Matters: The Hidden Cost of Steroids

Congenital Adrenal Hyperplasia is not just about hormone imbalance.

The real issue:

Patients rely on supraphysiologic steroid doses to suppress:

• Adrenocorticotropic hormone (ACTH)
• Excess androgens

The consequence:

Long-term glucocorticoid exposure leads to:

• Obesity and diabetes
• Bone density loss
• Cardiovascular disease
• Mental health issues

So treatment itself becomes a second disease burden. That’s the core problem CRENESSITY is trying to solve.

The Mechanism: A Non-Steroid Approach

CRENESSITY works differently.

Instead of replacing hormones, it:

• Blocks CRF1 receptors in the pituitary
• Reduces ACTH production
• Lowers androgen excess upstream

The result:

• Less need for high-dose steroids
• More physiologic replacement levels

Translation: Control the root signal → reduce downstream over-treatment.

Inside the CAHtalyst Study

This wasn’t a small dataset.

Trial snapshot:

• Phase III, global registrational program
• Largest interventional study in CAH
• Adult cohort: 182 patients

At 24 months:

• Mean GC dose dropped from 17.6 → 10.6 mg/m²/day
• ~69% achieved physiologic dosing (vs 0% at baseline)
• High retention rate (>80%)

Most importantly:

• Hormonal control was maintained
• No new safety concerns emerged

That last point is critical for long-term adoption.

What Clinicians Should Pay Attention To?

The data signals three practical shifts:

1. Steroid Minimization Is Now Feasible

Not theoretical—clinically demonstrated over 2 years.

2. Regimen Simplification

• Fewer doses
• Elimination of potent steroids like dexamethasone

3. Long-Term Safety Narrative Improves

• No new signals
• Consistent tolerability

This strengthens the case for chronic use, not just short-term optimization.

The Devil’s Advocate View

Before calling this a new standard of care, let’s stress-test it.

1. Patients Still Need Steroids

• CRENESSITY reduces dose—but doesn’t replace glucocorticoids
• Risk of adrenal crisis remains if dosing is mismanaged

2. Real-World Adherence Is Unproven

• Twice-daily oral therapy
• Requires coordination with steroid dosing

3. Cost vs Benefit Question

• Will payers support widespread use for a rare disease?
• Especially when steroids are cheap

4. Long-Term Outcomes Still Evolving

• 2 years is strong—but CAH is lifelong
• Cardiometabolic benefit needs longer validation

Bigger Picture: A Shift in Endocrine Treatment Strategy

CRENESSITY reflects a broader trend:

• Move away from blunt hormone replacement
• Toward targeted pathway modulation

Instead of compensating for the disease, you control the signaling that causes it.

Bottom Line

CRENESSITY’s two-year data does something meaningful:

• Reduces steroid burden
• Maintains disease control
• Shows durability over time

That combination is rare in endocrine disorders. But the real test is still ahead: Will this translate into better lifelong outcomes—or just cleaner short-term management?